Spelling suggestions: "subject:"doseresponse arelationship, drug."" "subject:"doseresponse arelationship, rug.""
1 |
Postsynaptic dorsal column spinal pathway does it play a role in cardiac pain? /Goodman Keiser, Melanie Dawn. January 2009 (has links) (PDF)
Thesis (Ph. D.)--University of Oklahoma. / Bibliography: leaves 109-119.
|
2 |
Dose-response modeling : evaluation, application, and development of procedures for benchmark dose analysis in health risk assessment of chemical substances /Sand, Salomon, January 2005 (has links)
Diss. (sammanfattning) Stockholm : Karolinska institutet, 2005. / Härtill 5 uppsatser.
|
3 |
Ribavirin - dose and concentration in treatment of chronic hepatitis C infected patients /Lindahl, Karin, January 2005 (has links)
Diss. (sammanfattning) Stockholm : Karolinska institutet, 2005. / Härtill 5 uppsatser.
|
4 |
Modulation of the conformaiton [sic] and function of membrane-bound anti-apoptotic Bcl-2 by potential anti-cancer drugsTian, Xuefei. January 2008 (has links) (PDF)
Thesis--University of Oklahoma. / Bibliography: leaves 71-78.
|
5 |
Pharmacological targeting of the mitochondrial phosphatase PTPMT1.Doughty-Shenton, D, Joseph, JD, Zhang, J, Pagliarini, DJ, Kim, Y, Lu, D, Dixon, JE, Casey, PJ 05 1900 (has links)
The dual-specificity protein tyrosine phosphatases (PTPs) play integral roles in the regulation of cell signaling. There is a need for new tools to study these phosphatases, and the identification of inhibitors potentially affords not only new means for their study, but also possible therapeutics for the treatment of diseases caused by their dysregulation. However, the identification of selective inhibitors of the protein phosphatases has proven somewhat difficult. PTP localized to mitochondrion 1 (PTPMT1) is a recently discovered dual-specificity phosphatase that has been implicated in the regulation of insulin secretion. Screening of a commercially available small-molecule library yielded alexidine dihydrochloride, a dibiguanide compound, as an effective and selective inhibitor of PTPMT1 with an in vitro concentration that inhibits response by 50% of 1.08 microM. A related dibiguanide analog, chlorhexidine dihydrochloride, also significantly inhibited PTPMT1, albeit with lower potency, while a monobiguanide analog showed very weak inhibition. Treatment of isolated rat pancreatic islets with alexidine dihydrochloride resulted in a dose-dependent increase in insulin secretion, whereas treatment of a pancreatic beta-cell line with the drug affected the phosphorylation of mitochondrial proteins in a manner similar to genetic inhibition of PTPMT1. Furthermore, knockdown of PTPMT1 in rat islets rendered them insensitive to alexidine dihydrochloride treatment, providing evidence for mechanism-based activity of the inhibitor. Taken together, these studies establish alexidine dihydrochloride as an effective inhibitor of PTPMT1, both in vitro and in cells, and support the notion that PTPMT1 could serve as a pharmacological target in the treatment of type II diabetes. / Dissertation
|
6 |
Doxorrubicina e ifosfamida em dose densa em pacientes com sarcomas de partes moles e expressão de ezrina como fator de prognóstico / Doxorrubicina e ifosfamida em dose densa em pacientes com sarcomas de partes moles e expressão de ezrina como fator de prognósticoAlmeida, Gustavo Fernandes Godoy 07 May 2010 (has links)
O prognóstico de pacientes portadores de sarcomas de partes moles (SPM) avançados é reservado. Aumentar o benefício de quimioterapia é necessário, sendo, uma das estratégias, quimioterapia em dose densa, a qual demonstrou benefício em câncer de mama. Por outro lado, a busca de um marcador prognóstico é importante para uma melhor seleção de pacientes que se beneficiariam de protocolo de tratamento mais intensivo. A ezrina é uma proteína que liga o citoesqueleto celular a proteínas de membrana, está associada a invasão celular e metástase e sua hiperexpressão tem sido associada a um pior prognóstico em sarcomas de partes moles. O objetivo deste estudo foi avaliar o papel de quimioterapia com dose densa em pacientes portadores de SPM de alto grau, avançados. O desfecho primário foi taxa de resposta e os secundários foram sobrevida global (SG), sobrevida livre de progressão (SLP), perfil de toxicidade, qualidade de vida e controle de dor. Avaliou-se também a expressão de ezrina por imunohistoquímica como marcador de prognóstico, com o intuito de estratificação da população que poderia se beneficiar mais desta abordagem intensificada. Neste estudo de fase II prospectivo, vinte e um pacientes foram incluídos. A idade mediana foi 37 anos (23-60) e extremidades inferiores foram o sítio primário mais comum. Sarcoma sinovial, leiomiossarcoma e sarcoma sem outras especificações foram as histologias mais frequentes. O protocolo consistiu de seis ciclos seqüenciais de doxorubicina 30mg/m2 D1-3 e ifosfamida 2,5g/m2 D1-5 a cada 14 e 21 dias, respectivamente, seguidos por sete dias de suporte hematopoiético. As intensidades de dose medianas de doxorrubicina e ifosfamida foram, respectivamente, 42mg/m2/semana e 3,63g/m2/semana (93% e 87% do planejado, respectivamente) e 15 pacientes (71%) receberam todo o tratamento. Toxicidades graus 3 e 4 foram observadas em 19 pacientes e em 77/105 ciclos, neutropenia febril em 6 ciclos (5 pacientes) e reduções da fração de ejeção de ventrículo esquerdo de pelo menos 10% em três pacientes. Não houve toxicidade renal provavelmente pela adminsitração da ifosfamida em duas horas. A resposta foi avaliada pelos critérios de RECIST, com três respostas parciais, totalizando uma taxa de resposta de 14%. Seis respostas deveriam ser observadas para que o estudo completasse a inclusão de todos os pacientes programados. Como não se atingiu a taxa de resposta prevista, o protocolo foi fechado. Três mortes precoces foram observadas com suspeita de toxicidade. Após seguimento mediano de 11 meses, a SLP e a SG medianas foram 8,1 e 20,1 meses respectivamente. Pacientes com sarcoma sinovial e idade inferior a 45 anos apresentaram maior sobrevida na análise univariada. A expresão de ezrina foi positiva em 10 pacientes (47%) e houve tendência a uma correlação direta entre sua expressão e sobrevida mais longa (p=0,1191). Todos os pacientes com histologia sinovial foram positivos para ezrina (teste de Fischer, p= 0,0325). Este esquema de quimioterapia sequencial com dose densa de doxorubicina e ifosfamida foi tóxico, a taxa de resposta foi baixa em um grupo de pacientes com doença avançada e não pode ser empregado na prática clínica diária fora de protocolo de pesquisa / Advanced soft tissue sarcoma (STS) patients have a dismal prognosis. Efforts to increase benefit from chemotherapy are needed and dose-dense chemotherapy could be an option, since this approach has demonstrated survival benefit in breast cancer. On the other hand, the identification of a prognostic marker is essential to stratify which patients could benefit most from intensified strategies. Ezrin is a member of the ERM (ezrin, radixin, moesin) cytoeskeleton-associated protein family associated with invasion and metastasis, and has been pointed as important prognostic marker in sarcomas. The objective of this study was to explore the role of dose-dense doxorubicin- and ifosfamide-based chemotherapy in advanced high grade STS patients. Primary endpoint was response rate and secondary endpoints were overall survival (OS), progression free survival (PFS), toxicity profile, quality of life and pain control evaluation. Tumor ezrin immunoreactivity was an exploratory endpoint as a predictor of response to chemotherapy and as a prognostic factor in this population, trying to find which patients could benefit most from this intensified strategy. This prospective, single arm, phase II study included 21 advanced STS patients. Median age was 37 years (23-60y) and lower limbs were the most frequent primary site. Synovial, leiomyo and unclassified sarcoma were the most common histologies. Protocol consisted of 6 cycles of sequential dose-dense doxorubicin 30 mg/m2 D1-3 and ifosfamide 2.5 g/m2 D1-5 every 14 and 21 days, respectively, followed by seven days of hematopoietic support. The median doxorubicin and ifosfamide dose-intensities were, respectively, 42 mg/m2/week and 3.63 g/m2/week (93% and 87% of planned, respectively) and 15 patients (71%) received all cycles. Grade 3/4 toxicities occurred in 19 patients and 77/105 cycles, febrile neutropenia in 5 patients (six cycles) and three LVEF drops of at least 10%, one symptomatic. No renal toxicity was observed what could occurred due to the two-hour-schedule of ifosfamide. Responses were evaluated by RECIST criteria and three patients presented partial response (response rate of 14%). Six responses were necessary to the inclusion of the target population, however, this was not observed and the study was closed. Three deaths were probably related to toxicity. After a median follow-up was 11 months, PFS and OS were 8.1 months and 20.1 months, respectively. Patients with synovial sarcoma and those younger than 45y presented better survival at univariate analysis. Ezrin expression was positive in 10 patients (47%) and a trend was observed for a correlation between positive ezrin expression and longer survival (p= 0.1191). There was a statistically significant correlation between positive ezrin expression and synovial hystology (Fishers exact test, p= 0.0325). This sequential dosedense doxorubicin/ifosfamide-based chemotherapy protocol was toxic, response rate was low in advanced STS patients and can not be considered for routine practice outside clinical trials
|
7 |
Response of motor and cognitive speed to increasing doses of methylphenidate in children diagnosed with attention deficithyperactivity disorderPolotskaia, Anna. January 2008 (has links)
This study has examined the effect of 3 doses of Methylphenidate (MPH) on the speed of motor and cognitive performance in children diagnosed with ADHD. Thirty children clinically diagnosed with Attention Deficit/Hyperactivity Disorder (ADHD) aged 6-12 years were recruited through the ADHD Clinic and the Severe and Disruptive Behavior Disorders Program at the Douglas Mental Health University Institute. The three doses of MPH were administered according to a double blind randomized cross-over three day trial (0.3; 0.5 0.8 mg/kg/day in a bid schedule). An improvement across all three doses of MPH on motor, cognitive and behavioural measures was observed. The improvement is significant at low doses of MPH and an increase of dose up to 0.8 mg/kg/day does not lead to further improvement of the speed of simple motor task, but might be beneficial to specific cognitive tasks. No deterioration was observed in association with higher doses of MPH.
|
8 |
Bone and kidney effects from cadmium exposure : dose effect and dose response relationships /Alfvén, Tobias, January 2002 (has links)
Diss. (sammanfattning) Stockholm : Karolinska institutet, 2002. / Härtill 5 uppsatser.
|
9 |
Doxorrubicina e ifosfamida em dose densa em pacientes com sarcomas de partes moles e expressão de ezrina como fator de prognóstico / Doxorrubicina e ifosfamida em dose densa em pacientes com sarcomas de partes moles e expressão de ezrina como fator de prognósticoGustavo Fernandes Godoy Almeida 07 May 2010 (has links)
O prognóstico de pacientes portadores de sarcomas de partes moles (SPM) avançados é reservado. Aumentar o benefício de quimioterapia é necessário, sendo, uma das estratégias, quimioterapia em dose densa, a qual demonstrou benefício em câncer de mama. Por outro lado, a busca de um marcador prognóstico é importante para uma melhor seleção de pacientes que se beneficiariam de protocolo de tratamento mais intensivo. A ezrina é uma proteína que liga o citoesqueleto celular a proteínas de membrana, está associada a invasão celular e metástase e sua hiperexpressão tem sido associada a um pior prognóstico em sarcomas de partes moles. O objetivo deste estudo foi avaliar o papel de quimioterapia com dose densa em pacientes portadores de SPM de alto grau, avançados. O desfecho primário foi taxa de resposta e os secundários foram sobrevida global (SG), sobrevida livre de progressão (SLP), perfil de toxicidade, qualidade de vida e controle de dor. Avaliou-se também a expressão de ezrina por imunohistoquímica como marcador de prognóstico, com o intuito de estratificação da população que poderia se beneficiar mais desta abordagem intensificada. Neste estudo de fase II prospectivo, vinte e um pacientes foram incluídos. A idade mediana foi 37 anos (23-60) e extremidades inferiores foram o sítio primário mais comum. Sarcoma sinovial, leiomiossarcoma e sarcoma sem outras especificações foram as histologias mais frequentes. O protocolo consistiu de seis ciclos seqüenciais de doxorubicina 30mg/m2 D1-3 e ifosfamida 2,5g/m2 D1-5 a cada 14 e 21 dias, respectivamente, seguidos por sete dias de suporte hematopoiético. As intensidades de dose medianas de doxorrubicina e ifosfamida foram, respectivamente, 42mg/m2/semana e 3,63g/m2/semana (93% e 87% do planejado, respectivamente) e 15 pacientes (71%) receberam todo o tratamento. Toxicidades graus 3 e 4 foram observadas em 19 pacientes e em 77/105 ciclos, neutropenia febril em 6 ciclos (5 pacientes) e reduções da fração de ejeção de ventrículo esquerdo de pelo menos 10% em três pacientes. Não houve toxicidade renal provavelmente pela adminsitração da ifosfamida em duas horas. A resposta foi avaliada pelos critérios de RECIST, com três respostas parciais, totalizando uma taxa de resposta de 14%. Seis respostas deveriam ser observadas para que o estudo completasse a inclusão de todos os pacientes programados. Como não se atingiu a taxa de resposta prevista, o protocolo foi fechado. Três mortes precoces foram observadas com suspeita de toxicidade. Após seguimento mediano de 11 meses, a SLP e a SG medianas foram 8,1 e 20,1 meses respectivamente. Pacientes com sarcoma sinovial e idade inferior a 45 anos apresentaram maior sobrevida na análise univariada. A expresão de ezrina foi positiva em 10 pacientes (47%) e houve tendência a uma correlação direta entre sua expressão e sobrevida mais longa (p=0,1191). Todos os pacientes com histologia sinovial foram positivos para ezrina (teste de Fischer, p= 0,0325). Este esquema de quimioterapia sequencial com dose densa de doxorubicina e ifosfamida foi tóxico, a taxa de resposta foi baixa em um grupo de pacientes com doença avançada e não pode ser empregado na prática clínica diária fora de protocolo de pesquisa / Advanced soft tissue sarcoma (STS) patients have a dismal prognosis. Efforts to increase benefit from chemotherapy are needed and dose-dense chemotherapy could be an option, since this approach has demonstrated survival benefit in breast cancer. On the other hand, the identification of a prognostic marker is essential to stratify which patients could benefit most from intensified strategies. Ezrin is a member of the ERM (ezrin, radixin, moesin) cytoeskeleton-associated protein family associated with invasion and metastasis, and has been pointed as important prognostic marker in sarcomas. The objective of this study was to explore the role of dose-dense doxorubicin- and ifosfamide-based chemotherapy in advanced high grade STS patients. Primary endpoint was response rate and secondary endpoints were overall survival (OS), progression free survival (PFS), toxicity profile, quality of life and pain control evaluation. Tumor ezrin immunoreactivity was an exploratory endpoint as a predictor of response to chemotherapy and as a prognostic factor in this population, trying to find which patients could benefit most from this intensified strategy. This prospective, single arm, phase II study included 21 advanced STS patients. Median age was 37 years (23-60y) and lower limbs were the most frequent primary site. Synovial, leiomyo and unclassified sarcoma were the most common histologies. Protocol consisted of 6 cycles of sequential dose-dense doxorubicin 30 mg/m2 D1-3 and ifosfamide 2.5 g/m2 D1-5 every 14 and 21 days, respectively, followed by seven days of hematopoietic support. The median doxorubicin and ifosfamide dose-intensities were, respectively, 42 mg/m2/week and 3.63 g/m2/week (93% and 87% of planned, respectively) and 15 patients (71%) received all cycles. Grade 3/4 toxicities occurred in 19 patients and 77/105 cycles, febrile neutropenia in 5 patients (six cycles) and three LVEF drops of at least 10%, one symptomatic. No renal toxicity was observed what could occurred due to the two-hour-schedule of ifosfamide. Responses were evaluated by RECIST criteria and three patients presented partial response (response rate of 14%). Six responses were necessary to the inclusion of the target population, however, this was not observed and the study was closed. Three deaths were probably related to toxicity. After a median follow-up was 11 months, PFS and OS were 8.1 months and 20.1 months, respectively. Patients with synovial sarcoma and those younger than 45y presented better survival at univariate analysis. Ezrin expression was positive in 10 patients (47%) and a trend was observed for a correlation between positive ezrin expression and longer survival (p= 0.1191). There was a statistically significant correlation between positive ezrin expression and synovial hystology (Fishers exact test, p= 0.0325). This sequential dosedense doxorubicin/ifosfamide-based chemotherapy protocol was toxic, response rate was low in advanced STS patients and can not be considered for routine practice outside clinical trials
|
10 |
Response of motor and cognitive speed to increasing doses of methylphenidate in children diagnosed with attention deficithyperactivity disorderPolotskaia, Anna. January 2008 (has links)
No description available.
|
Page generated in 0.0931 seconds